ALDX · Aldeyra Therapeutics, Inc.
Market Cap
$89.58M
Shares
60.33M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.49
Open$1.52
Day$1.48–1.56
52W close$1.24–5.86
Avg vol 30d850K
Short int3.3M · 5.5% float · 3.8d
Short vol42%
Last earningsMay 4, 2023
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−52%
below
Price vs 50-day avg
−15%
below
RSI (14)
40
neutral
MACD trend
Positive
52-week position
5%
near low
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−72%
trailing
YTD return
−71%
this year
Relative strength
−85%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-16% holders QoQ · +19 funds added
Insider flow
Accumulating
Net +$418.5K over 90 days · 0% sells
Short interest
Falling
5.51% of float · ▼ -2.9% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
108 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
EPS growth
+40%
Y/Y
Free cash flow
$-33.3M
Balance sheet
$54.7M
net cash
Quant / Vol
risk profile
Volatility
112%
annualized · 1-yr
Max drawdown
−79%
past year
ATR
6.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−52%
Bearish
Price vs 50-day avg
−15%
Bearish
RSI (14)
40
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-16% holders QoQ · +19 funds added
Insider flow
Accumulating
Net +$418.5K over 90 days · 0% sells
Short interest
Falling
5.51% of float · ▼ -2.9% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
108 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 5%
Range high $6
vs 200-day avg -52%
vs 50-day avg -15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALDX
this stock
Aldeyra Therapeutics, Inc.
|
$89.58M | -71.3% | — | — | 5.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALDX | -2.3% | -3.6% | -71.8% | -3.6% | -71.3% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -2.8% | -6.6% | -85.2% | -6.6% | -84.2% |
Key facts
CIK
1341235
CUSIP
01438T106
13F (30d)
90 filings
88 filers
Visit website
Investor relations